ArticleAging and disease2025
Interaction between Brain Natriuretic Peptide and QTc Prolongation on Mortality in Patients with Stroke-Heart Syndrome.
Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke-heart syndrome (SHS) is associated with early mortality in patients with acute ischemic stroke (AIS). However, reliable methods for timely risk stratification remain elusive. Combined monitoring of neurohormonal activation and electrocardiography may help identifying early mortality risk in SHS patients. This study investigates the interaction between elevated BNP and QTc prolongation on short-term mortality in SHS patients. This cohort study included patients with suspected AIS and concomitant SHS. SHS is defined as new-onset cardiac dysfunction after AIS, including acute coronary syndrome, heart failure, and arrhythmias. All patients underwent laboratory tests and electrocardiographic evaluations. Prolonged QTc was defined as >430 milliseconds (ms) in males and >450 ms in females. Patients were followed up for three months, and the study outcomes were all-cause mortality and cardiovascular and cerebrovascular disease (CCVD) mortality. Cox regression models were used to assess the relationship between BNP, QTc interval, and mortality, and the interaction between BNP and the QTc interval on mortality was analyzed. A total of 448 patients were enrolled in this analysis. Prolonged QTc was present in 217 patients (48.44%). Elevated BNP was associated with prolonged QTc (OR 1.90; 95% CI, 1.20-3.01, p=0.006). Elevated BNP, but not prolonged QTc, increased the risk of all-cause and CCVD mortality (HR 5.94; 95% CI, 1.22-29.03, p=0.028 and HR 5.48; 95% CI, 1.01-29.70, p=0.048, respectively). There was a significant interaction between elevated BNP and prolonged QTc on all-cause mortality (p for interaction <0.001). Patients with prolonged QTc and higher BNP had highest risk of all-cause mortality (HR 4.92, 95% CI, 1.03-23.39, p=0.045). This study highlights a significant interaction between prolonged QTc and elevated BNP levels in predicting short-term all-cause mortality among AIS patients with SHS. Prolonged QTc emerges as a critical marker of increased mortality risk, particularly in patients with elevated BNP levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.